伴与不伴胰高血糖素样肽1受体激动剂使用时SGLT2抑制剂的疗效与安全性:SMART-C协作随机对照试验Meta分析
该协作Meta分析纳入12项随机双盲安慰剂对照试验中73238例糖尿病患者,其中3065例(4.2%)基线使用GLP-1受体激动剂。结果显示,无论是否使用GLP-1受体激动剂,SGLT2抑制剂对主要不良心血管事件、心力衰竭住院或心血管死亡、慢性肾脏病进展及eGFR变化率的影响均一致,且严重不良事件更少。
要点
- 无论是否使用GLP-1受体激动剂,SGLT2抑制剂对心血管和肾脏结局的效应一致。
- SGLT2抑制剂组严重不良事件少于安慰剂组,与GLP-1受体激动剂使用无关。
- 结果支持指南推荐联合使用SGLT2抑制剂与GLP-1受体激动剂以改善心肾代谢结局。
核心结论
- SGLT2抑制剂对心血管和肾脏结局的效应与背景使用GLP-1受体激动剂无关,提示这两类循证治疗具有独立效应。
- 作者认为这些发现支持临床实践指南推荐联合使用这两类药物以改善心血管和肾脏代谢结局。
研究设计与样本
- SGLT2抑制剂心肾试验者联盟协作Meta分析,仅纳入糖尿病患者。
- 共纳入12项随机双盲安慰剂对照试验,73238例糖尿病患者中3065例(4.2%)基线使用GLP-1受体激动剂。
- 从各试验Cox回归模型获取治疗效应,采用逆方差加权Meta分析合并。
主要发现
- 主要不良心血管事件:使用GLP-1受体激动剂者HR 0.81(95%CI 0.63-1.03),未使用者HR 0.90(95%CI 0.86-0.94),异质性p=0.31。
- 心力衰竭住院或心血管死亡:使用GLP-1受体激动剂者HR 0.76(95%CI 0.57-1.01),未使用者HR 0.78(95%CI 0.74-0.82),异质性p=0.90。
- 慢性肾脏病进展:使用GLP-1受体激动剂者HR 0.65(95%CI 0.46-0.94),未使用者HR 0.67(95%CI 0.62-0.72),异质性p=0.81。
- eGFR随时间变化率:异质性p=0.92。
- 严重不良事件:使用GLP-1受体激动剂者相对风险0.87(95%CI 0.79-0.96),未使用者0.91(95%CI 0.89-0.93),异质性p=0.41,均少于安慰剂组。
关键数值与推荐
- 主要不良心血管事件定义为非致死性心肌梗死、非致死性卒中或心血管死亡。
- 慢性肾脏病进展定义为eGFR下降≥40%、肾衰竭(eGFR<15 mL/min/1.73 m2、慢性透析或肾移植)或肾衰竭死亡。
临床怎么用
- 原文结论指出,这些发现支持临床实践指南推荐联合使用SGLT2抑制剂与GLP-1受体激动剂以改善心血管和肾脏代谢结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the benefits of SGLT2 inhibitors are consistent in patients receiving and not receiving GLP-1 receptor agonists. METHODS: We conducted a collaborative meta-analysis of trials included in the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium, restricted to participants with diabetes. Treatment effects from individual trials were obtained from Cox regression models and pooled using inverse variance weighted meta-analysis. The two main cardiovascular outcomes assessed included major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death), and hospitalisation for heart failure or cardiovascular death. The main kidney outcomes assessed were chronic kidney disease progression (≥40% decline in estimated glomerular filtration rate [eGFR], kidney failure [eGFR <15 mL/min/1·73 m2, chronic dialysis, or kidney transplantation], or death due to kidney failure), and the rate of change in eGFR over time. Safety outcomes were also assessed. FINDINGS: Across 12 randomised, double-blind, placebo-controlled trials, 3065 (4·2%) of 73 238 participants with diabetes were using GLP-1 receptor agonists at baseline. SGLT2 inhibitors reduced the risk of major adverse cardiovascular events in participants both receiving and not receiving GLP-1 receptor agonists (hazard ratio [HR] 0·81, 95% CI 0·63-1·03 vs 0·90, 0·86-0·94; p-heterogeneity=0·31). Effects on hospitalisation for heart failure or cardiovascular death (0·76, 0·57-1·01 vs 0·78, 0·74-0·82; p-heterogeneity=0·90) and chronic kidney disease progression (0·65, 0·46-0·94 vs 0·67, 0·62-0·72; p-heterogeneity=0·81) were also consistent regardless of GLP-1 receptor agonist use, as was the effect on the chronic rate of change in eGFR over time (heterogeneity=0·92). Fewer serious adverse events occurred with SGLT2 inhibitors compared with placebo, irrespective of GLP-1 receptor agonist use (relative risk 0·87, 95% CI 0·79-0·96 vs 0·91, 0·89-0·93; p-heterogeneity=0·41). INTERPRETATION: The effects of SGLT2 inhibitors on cardiovascular and kidney outcomes are consistent regardless of the background use of GLP-1 receptor agonists. These findings suggest independent effects of these evidence-based therapies and support clinical practice guidelines recommending the use of these agents in combination to improve cardiovascular and kidney metabolic outcomes. FUNDING: National Health and Medical Research Council of Australia and the Ramaciotti Foundation.
引用
- Apperloo EM, Neuen BL, Fletcher RA, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024. PMID: 38991584. doi:10.1016/S2213-8587(24)00155-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。